Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Trial Type:  Treatment
Treatment/Intervention:  histone deacetylase inhibitor therapy, histone deacetylase targeted therapy
Results 1-25 of 76 for your search:
Start Over
Study of KW-0761 Versus Vorinostat in Relapsed/Refractory CTCL
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: 0761-010, NCI-2012-02782, NCT01728805
Exemestane with or without Entinostat in Treating Patients with Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: E2112, NCI-2014-00746, ECOG-E2112, NCT02115282
Entinostat in Combination with Aldesleukin in Treating Patients with Metastatic Kidney Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: I 145208, NCI-2012-02900, CDR0000662915, NCI 7870, NCT01043159, 7870, NCT01038778
Vorinostat and Combination Chemotherapy with Rituximab in Treating Patients with HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: AMC-075, NCI-2011-02508, AMC #75, CDR0000683379, NCT01193842
Vorinostat and Etoposide in Treating Younger Patients With Refractory or Relapsed Solid Tumors
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 4 to 21
Trial IDs: 10-096, NCI-2011-00493, NCT01294670
Lenalidomide and Romidepsin with or without Dexamethasone in Treating Patients with Recurrent or Refractory Hodgkin Lymphoma, Mature T-cell Lymphoma, or Multiple Myeloma
Phase: Phase II, Phase I
Type: Treatment
Age: 18 to 80
Trial IDs: 1112009392, NCI-2015-00921, RM-PTCL-PI-0021, NCT01742793
Romidepsin and Lenalidomide in Treating Patients with Relapsed or Refractory Lymphoma or Myeloma
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 12-170, NCI-2013-00005, NCT01755975
Vorinostat, Gemcitabine Hydrochloride, and Docetaxel in Treating Patients With Soft Tissue Sarcoma That is Metastatic or Cannot Be Removed By Surgery
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 12-104, NCI-2013-01735, UPCI 12-104, NCT01879085
Romidepsin and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients with Metastatic Inflammatory Breast Cancer
Phase: Phase II, Phase I
Type: Treatment
Age: Over 18
Trial IDs: 13C.387, NCI-2013-01695, 080-38270-J94401, 2013-35, NCT01938833
Pralatrexate and Romidepsin in Treating Patients with Relapsed or Refractory Lymphoma or Multiple Myeloma
Phase: Phase II, Phase I
Type: Treatment
Age: Over 18
Trial IDs: AAAJ5656, NCI-2014-01986, NCT01947140
ACY-1215 (Ricolinostat) in Combination With Pomalidomide and Low-dose Dex in Relapsed-and-Refractory Multiple Myeloma
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: ACE-MM-102, NCI-2014-00978, NCT01997840
Azacitidine and Romidepsin in Treating Patients With Relapsed or Refractory Lymphoid Malignancies
Phase: Phase II, Phase I
Type: Treatment
Age: Over 18
Trial IDs: AAAM3752, NCI-2014-00121, NCT01998035
Safety Study of Mocetinostat in Combination With Azacitidine in Subjects With MDS
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 0103-014, NCI-2013-02087, NCT02018926
HDAC6 Inhibitor ACY-1215 in Treating Patients with Relapsed or Refractory Non-Hodgkin Lymphoma or Hodgkin Lymphoma
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: AAAM4054, NCI-2014-01521, IRB-AAAM4054, NCT02091063
Rituximab, Romidepsin, and Lenalidomide in Treating Patients with Recurrent or Refractory B-cell Non-Hodgkin Lymphoma
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: MC1288, NCI-2014-02186, RM-FOL-PI-0034, NCT02281279
Carfilzomib, Romidepsin, and Lenalidomide in Treating Patients with Relapsed or Refractory B-cell and T-cell Lymphomas
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 14-179, NCI-2015-00109, NCT02341014
Cisplatin and Romidepsin in Treating Patients with Locally Recurrent or Metastatic Triple Negative Breast Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: RM-CL-PI-002783, NCI-2015-01524, RM-CL-BRST-PI-002783, STUDY00002219, NCT02393794
Mocetinostat and Brentuximab Vedotin in Treating Patients with Relapsed or Refractory Hodgkin Lymphoma
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 14-232, NCI-2015-00780, NCT02429375
Ph1b/2 Dose-Escalation Study of Entinostat With Pembrolizumab in NSCLC With Expansion Cohorts in NSCLC and Melanoma
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: SNDX-275-0601, NCI-2015-01180, NCT02437136
Romidepsin in Conditioning and Maintenance in Patients with T-cell Leukemia or Lymphoma Undergoing Donor Stem Cell Transplant
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 to 70
Trial IDs: 2015-0047, NCI-2015-01555, NCT02512497
Pembrolizumab and Vorinostat in Treating Patients with Recurrent Squamous Cell Head and Neck Cancer or Salivary Gland Cancer That Is Metastatic and/or Cannot Be Removed by Surgery
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 9383, NCI-2015-01310, MK-3475, NCT02538510
Lenalidomide and High-Dose Chemotherapy before Stem Cell Transplant in Treating Patients with Relapsed or Refractory, Diffuse Large B-Cell Lymphoma of the ABC Subtype
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 15 to 65
Trial IDs: 2015-0558, NCI-2015-01938, NCT02589145
Temozolomide and Vorinostat in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: HEMAML0017, NCI-2012-00229, 22794, NCT01550224
Vorinostat in Treating Patients with Metastatic Melanoma of the Eye
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: AAAO5917, NCI-2012-00860, CUMC-IRBAAAO5917, MSKCC-12-027, 9111, 12-027, NCT01587352
Belinostat and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed Aggressive B-Cell Non-Hodgkin Lymphoma
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 12-0288-04, NCI-2012-01131, NCT01686165
Start Over